Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,720,000 shares, a decrease of 15.5% from the January 15th total of 3,220,000 shares. Approximately 24.2% of the shares of the stock are short sold. Based on an average trading volume of 477,000 shares, the days-to-cover ratio is currently 5.7 days.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR traded down $0.12 during midday trading on Monday, hitting $6.08. The company had a trading volume of 477,987 shares, compared to its average volume of 671,338. Jasper Therapeutics has a twelve month low of $4.55 and a twelve month high of $31.01. The stock has a market cap of $91.21 million, a price-to-earnings ratio of -1.28 and a beta of 2.11. The business’s 50-day simple moving average is $12.46 and its 200-day simple moving average is $17.43.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its position in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Jasper Therapeutics in the fourth quarter valued at approximately $223,000. Finally, Tema Etfs LLC acquired a new position in Jasper Therapeutics in the fourth quarter valued at approximately $266,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. UBS Group assumed coverage on shares of Jasper Therapeutics in a research report on Thursday. They set a “buy” rating and a $38.00 price target for the company. HC Wainwright lowered their price objective on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Royal Bank of Canada reduced their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics presently has an average rating of “Buy” and an average price target of $64.44.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.